- Clovis Oncology (NASDAQ:CLVS) dips 7% premarket on modest volume. Investors appear unimpressed with Phase 2 results for CO-1686 (rociletinib), the company's mutant-selective EGFR inhibitor for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations including the primary resistance mutation T790M.
- The objective response rate (ORR) in 27 evaluable T790M-positive patients receiving either 625 mg or 500 mg rociletinib twice daily was 67%. The ORR was comparable across the two dose groups. The disease control rate was 89% and also comparable across the dose groups. Median progression-free survival (PFS) was 10.4 months.
- The ORR in 11 evaluable T790M-negative patients treated with the same two doses was 36%. Median PFS was 7.5 months.
- The company's clinical development of CO-1686 is ongoing, with patient recruitment underway in several new studies.